Status:
UNKNOWN
Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study"
Lead Sponsor:
University of Bologna
Conditions:
Enterococcal Bacteraemia
Enterococcus Faecalis Infection
Eligibility:
All Genders
18+ years
Brief Summary
Prospective, multicenter, observational study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis bloodstream infection (EF-BSI)...
Eligibility Criteria
Inclusion
- Adult (\>18 years)
- First monomicrobial EF-BSI
- Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy
- Written informed consent
Exclusion
- Short term (within 3 days from BSI) mortality
- Other concomitant infection
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04070820
Start Date
September 1 2019
End Date
March 1 2021
Last Update
March 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Infectious Disease Unit - S.Orsola Malpighi Hospital
Bologna, Italy